Velpatasvir D6
| Product Name | Velpatasvir D6 |
|---|---|
| Alternate Names | Velpatasvir Stable Isotopes, Stable Isotopes of Velpatasvir |
| CAT No. | CS-O-16550 |
| CAS No. | 1377049-84-7(Unlabeled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 889.04 g/mol |
| Mol. For. | C49H48D6N8O8 |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Velpatasvir |
| Purity | 95% |
| Therapeutic | Antiretroviral / Anti-HIV |
| Smileys | O=C(N([C@H]1C)[C@@H](CC1)C2=NC3=C(C(C=C(OCC4=CC(C5=CN=C([C@H](C[C@H](COC)C6)N6C([C@@H](C7=CC=CC=C7)NC(OC([2H])([2H])[2H])=O)=O)N5)=CC=C84)C8=C9)=C9C=C3)N2)[C@@H](C(C)C)NC(OC([2H])([2H])[2H])=O |
| Canonical Smiles | CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC |
| InchIKey | FHCUMDQMBHQXKK-CDIODLITSA-N |
| Inchl | InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1 |
| IUPAC | methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Velpatasvir D6 is a deuterated form of velpatasvir, which is an antiviral medication used in the treatment of chronic hepatitis C virus (HCV) infection. Velpatasvir D6 is a potent inhibitor of the HCV NS5A protein, which plays a crucial role in viral replication and assembly. By inhibiting this protein, velpatasvir D6 prevents the virus from reproducing and spreading, thereby reducing the viral load in the body.
Velpatasvir D6 is typically administered as part of a combination therapy with other antiviral drugs such as sofosbuvir and ribavirin. This combination therapy has been found to be highly effective in treating all six genotypes of HCV with minimal side effects.
Chemically, velpatasvir D6 is a white to off-white powder with a molecular formula of C49H51D6N8O9S2. It has a molecular weight of 969.18 g/mol, and its chemical structure consists of a pyrrolopyridine core with a fused quinoline ring system.
In terms of pharmacokinetics, velpatasvir D6 is rapidly absorbed after oral administration, with peak plasma concentrations reached within 3 to 4 hours. It has a long half-life of approximately 15 hours, allowing for once-daily dosing. Velpatasvir D6 is primarily metabolized in the liver, and its metabolites are excreted in the urine and feces.
Overall, velpatasvir D6 is a valuable medication in the treatment of chronic HCV infection, and its chemical properties and pharmacokinetics make it an effective and safe option for patients.
Get an Instant Quote
Related Compounds
Velpatasvir-13Cd3 | Velpatasvir 13CD3 | Velpatasvir 13C2 D6 |